Invasive fungal infections and their risk factors were prospectively assessed in 130 consecutive liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. Eleven percent (14) of the 130 patients had 17 episodes of invasive fungal infections. These included candidiasis (5%; 6 patients), cryptococcosis (5%; 6), aspergillosis (3%; 4), and chromomycosis (1%; 1). An elevated pretransplantation creatinine level, requirement of dialysis (pretransplantation or posttransplantation), duration of intensive care unit stay after transplantation surgery, and antibiotic use (other than for prophylaxis) within 4 weeks of transplantation were significant risk factors for fungal infections occurring within 100 days of transplantation. For fungal infections occurring after 100 days, persistence of renal dysfunction (serum creatinine level of >2.5 mg/dL at 3 months), dialysis, and histopathologically documented recurrence of hepatitis C virus hepatitis were significant risk factors. Mortality was significantly higher among patients with fungal infections than among all other patients (57% vs. 15%; P = .0009). Our study identified specific risk factors for invasive fungal infections in liver transplant recipients receiving tacrolimus; strategies to prevent fungal infections or to initiate early antifungal therapy might be most effectively targeted at these patients.
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Invasive fungal infections have been recognized as a major complication and a significant cause of death for transplant recipients. Fungal infections have been reported in 7%-42% of liver transplant recipients [1] [2] [3] [4] [5] [6] [7] and account for 20%-30% of all major infections after liver transplantation. Recipients of orthotopic liver transplantation are uniquely susceptible to fungal infections as compared with other solid-organ transplant recipients [7] .
It has been proposed that liver transplant surgery, by disrupting the integrity of the biliary tract and small bowel, promotes dissemination of gastrointestinal candidiasis [6] . Prolonged operation time, retransplantation, increased transfusion requirements, pretransplantation corticosteroid usage, use of antibiotics, and cytomegalovirus (CMV) infection have been well recognized as risk factors for invasive fungal infections in liver transplant recipients receiving cyclosporine [1, 2, 6] .
A new immunosuppressive agent, tacrolimus (FK506), is being increasingly employed as rescue therapy or as a primary immunosuppressive agent in liver transplant recipients. Both tacrolimus and cyclosporine inhibit T lymphocyte activation by blocking IL-2 production, although the in vitro immunosuppressive effect of tacrolimus is several hundredfold greater than that of cyclosporine [8] . Tacrolimus inhibited the appearance of IL-2 receptors on T cells in human mixed lymphocyte culture at concentrations 32-100 times lower than did cyclosporine [9] . Use of tacrolimus has been associated with a lower requirement of adjunctive immunosuppression, e.g., with corticosteroids [10] .
To our knowledge, no study has assessed the risk factors for fungal infections in liver transplant recipients receiving tacrolimus. In this report on our prospective study we summarize the fungal infections and evaluate the risk factors for their development in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. The primary objective was to identify risk factors that may be amenable to modification or factors that may serve to target patients for antifungal prophylaxis or early institution of antifungal therapy.
Methods
At a newly established liver transplantation program at the Pittsburgh Veterans Affairs Medical Center, consecutive patients undergoing liver transplantation were prospectively observed for infections. Between October 1989 and October 1995, 130 consecutive adult patients underwent 140 liver transplantations and comprised the study population. All patients were followed until death or time of preparation of this article. The median duration of follow-up for the living patients was 38 months (range, 3-74 months).
Immunosuppression. All patients received tacrolimus and low-dose prednisone as immunosuppressive agents. One gram of methylprednisolone was given immediately after revascularization of the graft. Twenty milligrams of methylprednisolone was given intravenously daily until the oral route was established, at which time 20 mg of prednisone was administered daily. During the subsequent months, the prednisone regimen was slowly tapered. Rejection episodes were treated with 1 g of methylprednisolone bolus, with or without steroid cycles (methylprednisolone given intravenously in four divided doses daily; the dose was tapered from 200 mg to 20 mg per day over 6 days). OKT3 was used for steroid-resistant rejection.
Antimicrobial prophylaxis. Perioperative prophylaxis consisted of administration of ampicillin and cefotaxime for 24 hours. Patients allergic to penicillin received clindamycin and aztreonam for 24 hours. Trimethoprim (80 mg) and sulfamethoxazole (400 mg) were used once daily indefinitely as prophylaxis against pneumocystis infection. Dapsone or aerosolized pentamidine was substituted for patients allergic to or unable to tolerate trimethoprim-sulfamethoxazole.
Selective bowel decontamination was performed during the initial posttransplantation intensive care unit (ICU) stay with use of 24 mL of a mixture of colistin (100 mg/20 mL), gentamicin (80 mg/20 mL), and nystatin (2 million units/20 mL), administered orally or via nasogastric tube four times daily. Acyclovir (600 mg daily) was administered for 1 month following transplantation as prophylaxis against herpes simplex virus. Preemptive treatment with ganciclovir for 7 days (upon CMV shedding) was employed as prophylaxis for CMV disease [11] .
Definition of infections. Stringent criteria were employed for the diagnosis of invasive fungal infections. Systemic candidal infections were defined as previously reported [2, 6] , i.e., with histopathologic and cultural evidence of tissue invasion revealed by biopsy or autopsy; by positive culture of a deep-tissue specimen (e.g., blood, CSF, or peritoneal fluid from an intraoperative or percutaneous aspirate specimen); or by the finding of deep-seated abscesses (open or percutaneous drainage or aspirate). Yeast colonization in isolated sites such as the oral cavity, upper respiratory tract, bronchial specimens, sputum, stool, or urine in the absence of tissue invasion was considered insufficient evidence of invasive candidal infection [1] . Noncandidal invasive fungal infections were diagnosed by either a positive blood culture (e.g., cryptococcosis) or evidence of tissue invasion on biopsy or autopsy (e.g., aspergillosis).
Risk factors for fungal infections. The following variables were assessed as risk factors for systemic fungal infections in our patients. Pretransplantation variables were age, sex, underlying liver disease, Child-Pugh score, United Network of Organ Sharing (UNOS) severity score, serum bilirubin level, serum creatinine level, requirement of dialysis, pretransplantation use of antibiotics (within 4 weeks of transplantation), ICU stay at any time before transplantation, and duration of ICU stay. Operative variables were donor age, donor sex, cold ischemic time, time of transplantation surgery, portal vein thrombosis, transfusion of packed RBCs, and type of bile duct anastomosis (this latter datum was available only for patients who received transplants after 1990, i.e., 111 patients).
Posttransplantation variables were antibiotic use (within 4 weeks of transplantation, excluding the prophylactic regimen), length of posttransplantation ICU stay, readmission to the ICU, number of abdominal and intrathoracic operations, dialysis, serum creatinine level at 3 months, histopathologically documented recurrence of hepatitis C virus hepatitis, retransplantation, CMV infection, CMV disease, biopsy-proven rejection, number of steroid boluses and recycles used, and the use of OKT3.
Fungal infections were considered early if they occurred within 100 days of transplantation and late if they occurred after 100 days. Risk factor analysis was stratified by early and late fungal infections. Pretransplantation and operative variables were included only in the analysis of early fungal infections (tables 1 and 2). Posttransplantation variables assessed as risk factors for early fungal infections included antibiotic use 100 days) , the initial transplantation -was used to assess the baseline variables [1] . For late retransplantation (after 100 days), the variables at retransplantation were used for analysis; none of the patients who underwent retransplantation had a fungal infection before the procedure.
Results
Characteristics of the study population. Of 130 patients included in the study, 98% (128) were male. The mean age was 47 years (range, 22-69 years). Their underlying liver diseases were hepatitis C virus infection (53%), alcoholic liver disease (45%), hepatitis B virus infection (9%), primary sclerosing cholangitis (10%), hepatocellular carcinoma (5%), cryptogenic cirrhosis (4%), metabolic liver disease (4%), and primary biliary cirrhosis (2%) (some patients had more than one underlying liver disease). According to the functionalstatus UNOS scale used until 1 April 1995, only 2% (3) of the 130 patients had a UNOS score of 2 (were at home while awaiting transplantation), 66% (86) were hospitalized (UNOS 3), and 32% (41) were in the ICU (UNOS 4) when the time for transplantation arrived.
Incidence and types of fungal infections. Eleven percent (14) of the 130 patients had a total of 17 episodes of invasive fungal infections. These included candidiasis (5%; 6 patients), cryptococcosis (5%; 6), aspergillosis (3%; 4), and chromomycosis (1%; 1).
Eighty-three percent (five) of the six patients with invasive candidiasis had candidemia. Candidemia was secondary to a liver abscess in one patient, an intravenous catheter in one, and a urinary tract infection in one; the portal of entry in two cases was unknown. The species isolated from the blood were Candida albicans (n = 2), Candida tropicalis (n = 2), and Torulopsis glabrata (n = 1). One patient had T glabrata peritonitis (secondary to perforated gut) without fungemia. Three of the six patients with candidiasis also had other fungal infections NOTE. HCV = hepatitis C virus. * Occurring after 100 days; patients who died within 100 days (n = 13) were excluded from this analysis.
t Not significant (P > .05).
(aspergillosis in two and cryptococcosis in one). The median time to onset of candidiasis was 39 days (range, 7-1,744 days) after transplantation. Cryptococcosis occurred a median of 292 days after transplantation (range, 74-650 days). Four of 6 patients with cryptococcosis had cutaneous and/or osteoarticular cryptococcal infection (biopsy proven in all cases) and 3 patients had pulmonary cryptococcosis (with cutaneous involvement in 1 case, meningitis in 1, and isolated pulmonary infection in 1).
Invasive aspergillosis occurred a median of 24 days (range, 10-238 days post-transplantation) in 3% (four) of the 130 patients. All patients had invasive pulmonary aspergillosis, and two of four patients had disseminated invasive aspergillosis. Cutaneous abscess due to chromomycosis developed in one patient.
Forty-three percent (six) of the 14 patients with fungal infections had early fungal infections, and 57% (eight) had late fungal infections. Early fungal infections were due to invasive candidiasis (n = 2), aspergillosis and candidiasis (n = 2), aspergillosis (n = 1), and cryptococcosis (n = 1). Late fungal infections were due to cryptococcosis (n = 4), cryptococcosis and candidiasis (n = 1), candidiasis (n = 1), aspergillosis (n = 1), and chromomycosis (n = 1).
Risk factors for fungal infections. For early fungal infection. (occurring within 100 days), pretransplantation serum creatinine level (P = .02), pretransplantation dialysis (P = .0005), posttransplantation dialysis (P = .005), duration of ICU stay after transplantation surgery (P = .001), and use of posttransplantation antibiotics within 4 weeks of transplantation, other than for prophylaxis (P = .02), were significant risk factors by univariate analysis.
Variables not significantly associated with early fungal infections are listed in tables 1 and 2. For fungal infections occurring after 100 days, only posttransplantation variables listed in table 3 were analyzed as risk factors. Serum creatinine level at 90 days (P = .033), dialysis (P = .045), serum creatinine level of >2.5 mg/dL at 90 days (P = .02), histopathologically documented recurrent hepatitis C virus hepatitis (P = .006), and biopsy-proven rejection (P = .05) were significant risk factors by univariate analysis. Variables not significantly associated with late fungal infections are listed in table 3.
Mortality. Overall mortality was significantly higher among patients with fungal infections than among those without fungal infections (57% [8 of 14] vs. 15% [17 of 116]; P = .009). Fungal infections were the direct cause of the deaths of 5 of 8 patients with fungal infections (aspergillosis in 4 and cryptococcosis in 1).
Discussion
Candida and Aspergillus species are the most frequently reported fungal pathogens causing infection following liver transplantation (table 4) . Studies in the United States of liver transplant recipients receiving cyclosporine have demonstrated that Candida species accounted for 77%-83% and Aspergillus species for 15%-20% of all fungal infections [7] . Cryptococcosis has been observed in 0.3%-1% of liver transplant recipients. Two European studies reported fungal infections in 13%-16.5% of the liver transplant recipients receiving cyclosporine [3, 4] . However, as in the studies in the United States, Candida species accounted for 56%-87% of all fungal infections. Invasive fungal infections were documented in 9% (two) of 22 liver transplant recipients who received tacrolimus [14] .
Fungal infections were observed in 11% of our liver transplant recipients receiving tacrolimus; these included candidiasis in 5% (6), cryptococcosis in 5% (6) and aspergillosis in 3% (4) of the 130 patients. Although a direct comparison with the previous reports may not be valid because of variations in definitions of fungal infections and methods of analysis, we found a relatively lower incidence of invasive candidiasis and a higher incidence of cryptococcal infections in our patients than the incidence rates described in earlier reports.
Systemic antifungal agents (amphotericin B or azoles) are not employed as prophylaxis at our institution. Routine employment of nystatin as part of selective bowel decontamination in the early postoperative period, a relatively lower requirement of corticosteroids with tacrolimus, or differences in surgical techniques may have accounted for a lower incidence of candidal infections in our patients.
In our study, an elevated serum creatinine level and requirement of dialysis were significant risk factors for both early and late fungal infections. It is conceivable that renal failure may be merely reflective of the overall complicated course and greater severity of illness, which may itself predispose these patients to fungal infections. On the other hand, the association between renal failure and fungal infections is biologically plausible; renal failure has been associated with defective cellmediated immunity and impaired granulocyte-macrophage function, which are the predominant host defenses against fungal pathogens [15] .
The association of fungal infections and our finding of renal dysfunction has also been noted in the literature. Level of serum creatinine, length of transplantation operation, retransplantation, and CMV infection were independently associated with fungal infections in a study of 158 patients undergoing liver transplantation between 1983 and 1990 [1] . Amount of fresh frozen plasma transfused and acute renal failure requiring dialysis were independent risk factors for systemic fungal infections in a European study [3] . In a report examining the risk factors for invasive aspergillosis following liver transplantation (when compared with colonization with Aspergillus species without invasive disease) elevated creatinine level and use of OKT3 were independently significant risk factors [16] .
Histopathologically documented recurrent hepatitis C virus hepatitis was a significant factor associated with late fungal infections in our patients. Fungal infections, particularly due to candidiasis and aspergillosis, usually do not occur after 3 months of liver transplantation. In our study 57% of the overall Renal failure significantly increased the risk for invasive fungal infections in our liver transplant recipients receiving tacrolimus. Strategies to prevent fungal infections or to initiate early antifungal therapy might be most efficiently directed at these high-risk patients. Finally, patients with recurrent hepatitis C virus hepatitis were identified as a unique subgroup susceptible to late fungal infections following liver transplantation.
